- Trial phase
- Preclinical
- Time to market
- Unknown, at least 4-6 years away if clinical trials succeed. IND filing is expected H2 2027, followed by Phase 1/2 trials that typically take 2-3 years, then pivotal trials.
- Why 2/10
- ABO-701 is preclinical with no hard, dated catalyst within the next ~12 months (IND filing expected H2 2027). It is a small pipeline asset at a company whose primary value driver is the already-approved, commercial-stage ZEVASKYN. Even a positive IND update would be a modest catalyst relative to the company's commercial execution story.
ABO-701 is too early-stage (preclinical, IND expected H2 2027) to drive ABEO's share price in the next 12 months. Investors should focus on ZEVASKYN commercial execution (patient treatment volumes, revenue growth, manufacturing yields) as the primary near-term value driver. Any ABO-701-related moves would be speculative and tied to broader pipeline sentiment rather than a hard catalyst.
Price Chart
Executive Summary
ABO-701 (PSMA-SIR-T) is a preclinical gene therapy candidate for prostate cancer that Abeona Therapeutics in-licensed in Q1 2026 for a $7.0M upfront payment. It uses a PSMA-targeted approach to deliver a gene therapy payload to prostate cancer cells. The drug remains in preclinical development with an IND filing expected in the second half of 2027, more than 12 months away. Abeona's primary value driver is ZEVASKYN, its already-approved and commercializing gene therapy for epidermolysis bullosa, which generated $11.4M in Q2 2026 revenue. ABO-701 is a small, early-stage pipeline asset with no near-term binary catalyst, making it a negligible factor for the stock in the next 12 months.
How It Works
ABO-701 is a gene therapy designed to target prostate cancer cells. It uses a modified virus (AAV vector) to deliver a therapeutic gene specifically to cells that express PSMA, a protein found at high levels on the surface of prostate cancer cells. The therapy is designed to enter those cancer cells and trigger an anti-tumor effect, essentially reprogramming the cancer cells to self-destruct or become visible to the immune system.
Trial Status
ABO-701 is in preclinical development. It was in-licensed by Abeona in Q1 2026 for a $7.0M upfront payment. The company expects to file an Investigational New Drug (IND) application with the FDA in the second half of 2027. No clinical trials have been initiated yet.
The Two-Sided Case
Upcoming Catalysts
- IND filing expected H2 2027 (more than 12 months out)
- No near-term binary catalysts for ABO-701 specifically
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ABEONA THERAPEUTICS INC. 8-K ABEO ·Originating report